2006•Journal of Bengbu Medical CollegeRequires access

Effect of COMxEP regimens in treating non-Hodgkin's lymphoma

Zhao Lun

Open publisher page 0 citations

Abstract

Objective:To evaluate the therapeutic effect and toxicity of COMxEP regimens in treatment of non-Hodgkin's lymphoma(NHL).Methods:Thirty-seven patients with intermediate-high grade NHL were treated with a combination chemotherapy of COMxEP.COMxEP regimen consisted of VP_(16),60-70 mg/m~2(iv gtt,Day1-5);MxT,6-8 mg/m~2(iv gtt,Day1);VCR,1.4 mg/m~2(iv,Day1,8);CTX,600-800 mg(iv,Day1,8);Pred,40-60 mg/day(po,Day1-5).One course lasted for 4 weeks and each patient received(4.8) courses on the average.Results:In the thirty seven patients receiving COMxEP regimen,complete remission(CR) rate was(67.6%),partial remission(PR) rate 21.6%,SD rate 14.3% and PD was no,and the overall response rate was 89.2%(33/37),with a median duration of 26 months.In the patients with refractory disease,CR rate was 53.8%,PR rate 30.8%,SD rate 15.4% and PD was no,and the overall response rate was 84.6%.The main side effects were bone marrow depression,enteron reaction and alopecie.Conclusions:COMxEP regimen is effective for patients with newly diagnosed or refractory disease,and the toxicity is tolerable.This regimen can be considered as a routine or salvage therapy for intermediate-high grade NHL.

About this research paper

What this paper is about

Objective:To evaluate the therapeutic effect and toxicity of COMxEP regimens in treatment of non-Hodgkin's lymphoma(NHL).Methods:Thirty-seven patients with intermediate-high grade NHL were treated with a combination chemotherapy of COMxEP.COMxEP regimen consisted of VP_(16),60-70 mg/m~2(iv gtt,Day1-5);MxT,6-8 mg/m~2(iv gtt,Day1);VCR,1.4 mg/m~2(iv,Day1,8);CTX,600-800 mg(iv,Day1,8);Pred,40-60 mg/day(po,Day1-5).One course lasted for 4 weeks and each patient received(4.8) courses on the average.Results:In the thirty seven patients receiving COMxEP regimen,complete remission(CR) rate was(67.6%),partial remission(PR) rate 21.6%,SD rate 14.3% and PD was no,and the overall response rate was 89.2%(33/37),with a median duration of 26 months.In the patients with refractory disease,CR rate was 53.8%,PR rate 30.8%,SD rate 15.4% and PD was no,and the overall response rate was 84.6%.The main side effects were bone marrow depression,enteron reaction and alopecie.Conclusions:COMxEP regimen is effective for patients with newly diagnosed or refractory disease,and the toxicity is tolerable.This regimen can be considered as a routine or salvage therapy for intermediate-high grade NHL.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To evaluate the therapeutic effect and toxicity of COMxEP regimens in treatment of non-Hodgkin's lymphoma(NHL).Methods:Thirty-seven patients with intermediate-high grade NHL were treated with a combination chemotherapy of COMxEP.COMxEP regimen consisted of VP_(16),60-70 mg/m~2(iv gtt,Day1-5);MxT,6-8 mg/m~2(iv gtt,Day1);VCR,1.4 mg/m~2(iv,Day1,8);CTX,600-800 mg(iv,Day1,8);Pred,40-60 mg/day(po,Day1-5).One course lasted for 4 weeks and each patient received(4.8) courses on the average.Results:In the thirty seven patients receiving COMxEP regimen,complete remission(CR) rate was(67.6%),partial remission(PR) rate 21.6%,SD rate 14.3% and PD was no,and the overall response rate was 89.2%(33/37),with a median duration of 26 months.In the patients with refractory disease,CR rate was 53.8%,PR rate 30.8%,SD rate 15.4% and PD was no,and the overall response rate was 84.6%.The main side effects were bone marrow depression,enteron reaction and alopecie.Conclusions:COMxEP regimen is effective for patients with newly diagnosed or refractory disease,and the toxicity is tolerable.This regimen can be considered as a routine or salvage therapy for intermediate-high grade NHL.

Key concepts: Medicine, Regimen, Internal medicine, Gastroenterology, Refractory (planetary science), Lymphoma, Complete remission, Chemotherapy

Related papers

Back to paper searchBrowse research topicsOriginal source
Effect of COMxEP regimens in treating non-Hodgkin's lymphoma — Research Paper | ScholarLens